Compare JVA & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | ITRM |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 24.3M |
| IPO Year | 2005 | 2018 |
| Metric | JVA | ITRM |
|---|---|---|
| Price | $3.67 | $0.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 35.5K | ★ 731.7K |
| Earning Date | 01-30-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.91 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $89,748,681.00 | $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $325.95 |
| P/E Ratio | $11.21 | ★ N/A |
| Revenue Growth | ★ 17.92 | N/A |
| 52 Week Low | $2.75 | $0.36 |
| 52 Week High | $9.93 | $2.10 |
| Indicator | JVA | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 32.72 |
| Support Level | $3.31 | $0.44 |
| Resistance Level | $3.74 | $0.49 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 80.77 | 0.78 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.